In December 2022, Atossa closed their previously announced investment in Dynamic Cell Therapies, Inc. (DCT), a privately held, venture capital backed, developer of CAR-T therapies. DCT is in the pre-clinical phase of developing controllable CAR-T cells to address difficult-to-treat cancers. Its platform technology of dynamic control of engineered T-cells is designed to improve the safety, efficacy, and durability of CAR-T cell therapies. While their initial focus is hematologic malignancies, their innovative approach could also have broad applicability in solid tumors and autoimmune diseases. Atossa's investment in DCT, which totaled $5 million, resulted in Atossa owning approximately 19% of the outstanding capital stock of DCT.

Attachments

Disclaimer

Atossa Therapeutics Inc. published this content on 12 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 January 2023 10:39:04 UTC.